nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Vinblastine—head and neck cancer	0.26	0.29	CbGbCtD
Canagliflozin—ABCC2—Docetaxel—head and neck cancer	0.214	0.239	CbGbCtD
Canagliflozin—ALB—Fluorouracil—head and neck cancer	0.175	0.195	CbGbCtD
Canagliflozin—ABCB1—Vinblastine—head and neck cancer	0.0848	0.0945	CbGbCtD
Canagliflozin—ABCB1—Docetaxel—head and neck cancer	0.0699	0.0779	CbGbCtD
Canagliflozin—CYP3A4—Vinblastine—head and neck cancer	0.0508	0.0566	CbGbCtD
Canagliflozin—CYP3A4—Docetaxel—head and neck cancer	0.0419	0.0467	CbGbCtD
Canagliflozin—Dapagliflozin—CYP1A1—head and neck cancer	0.0142	1	CrCbGaD
Canagliflozin—UGT1A9—Arylamine metabolism—NAT2—head and neck cancer	0.00834	0.125	CbGpPWpGaD
Canagliflozin—UGT2B4—Phase II conjugation—NAT2—head and neck cancer	0.00263	0.0395	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—TGFA—head and neck cancer	0.00193	0.029	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—TGFA—head and neck cancer	0.00193	0.029	CbGpPWpGaD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00186	0.0279	CbGpPWpGaD
Canagliflozin—UGT1A9—Estrogen metabolism—GSTM1—head and neck cancer	0.00171	0.0257	CbGpPWpGaD
Canagliflozin—UGT1A9—Estrogen metabolism—CYP1A1—head and neck cancer	0.00162	0.0244	CbGpPWpGaD
Canagliflozin—UGT2B4—Biological oxidations—NAT2—head and neck cancer	0.00154	0.0231	CbGpPWpGaD
Canagliflozin—UGT2B4—Metapathway biotransformation—NAT2—head and neck cancer	0.00152	0.0228	CbGpPWpGaD
Canagliflozin—UGT2B4—Phase II conjugation—GSTM1—head and neck cancer	0.0013	0.0195	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—GSTM1—head and neck cancer	0.00112	0.0169	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—GSTM1—head and neck cancer	0.00112	0.0169	CbGpPWpGaD
Canagliflozin—Rash generalised—Docetaxel—head and neck cancer	0.00108	0.0476	CcSEcCtD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—CEBPA—head and neck cancer	0.00104	0.0157	CbGpPWpGaD
Canagliflozin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00103	0.0155	CbGpPWpGaD
Canagliflozin—Prurigo—Docetaxel—head and neck cancer	0.000998	0.0438	CcSEcCtD
Canagliflozin—UGT1A9—Phase II conjugation—NAT2—head and neck cancer	0.000973	0.0146	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00092	0.0138	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00092	0.0138	CbGpPWpGaD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000873	0.0131	CbGpPWpGaD
Canagliflozin—Blood urea increased—Hydroxyurea—head and neck cancer	0.000837	0.0368	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—UROD—head and neck cancer	0.00082	0.0123	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—UROD—head and neck cancer	0.00082	0.0123	CbGpPWpGaD
Canagliflozin—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.000806	0.0354	CcSEcCtD
Canagliflozin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.000798	0.012	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.000765	0.0115	CbGpPWpGaD
Canagliflozin—UGT2B4—Biological oxidations—GSTM1—head and neck cancer	0.000759	0.0114	CbGpPWpGaD
Canagliflozin—UGT2B4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000749	0.0113	CbGpPWpGaD
Canagliflozin—UGT2B4—Biological oxidations—CYP1A1—head and neck cancer	0.00072	0.0108	CbGpPWpGaD
Canagliflozin—UGT2B4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00071	0.0107	CbGpPWpGaD
Canagliflozin—Renal failure acute—Hydroxyurea—head and neck cancer	0.000697	0.0306	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—YAP1—head and neck cancer	0.000677	0.0102	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—head and neck cancer	0.000663	0.00997	CbGpPWpGaD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—CCND1—head and neck cancer	0.000649	0.00976	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—UROD—head and neck cancer	0.000633	0.00953	CbGpPWpGaD
Canagliflozin—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000603	0.0265	CcSEcCtD
Canagliflozin—Rash erythematous—Docetaxel—head and neck cancer	0.000602	0.0264	CcSEcCtD
Canagliflozin—Breast disorder—Hydroxyurea—head and neck cancer	0.000582	0.0255	CcSEcCtD
Canagliflozin—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00058	0.0255	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—NAT2—head and neck cancer	0.000569	0.00856	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—NAT2—head and neck cancer	0.000561	0.00844	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFA—head and neck cancer	0.000552	0.0083	CbGpPWpGaD
Canagliflozin—Pancreatitis—Hydroxyurea—head and neck cancer	0.000545	0.024	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—TGFA—head and neck cancer	0.000538	0.0081	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000538	0.00809	CbGpPWpGaD
Canagliflozin—Photosensitivity—Fluorouracil—head and neck cancer	0.000528	0.0232	CcSEcCtD
Canagliflozin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000503	0.00757	CbGpPWpGaD
Canagliflozin—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000483	0.00727	CbGpPWpGaD
Canagliflozin—UGT1A9—Phase II conjugation—GSTM1—head and neck cancer	0.00048	0.00723	CbGpPWpGaD
Canagliflozin—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.000458	0.00689	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	0.000457	0.00687	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000422	0.00635	CbGpPWpGaD
Canagliflozin—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.000421	0.00633	CbGpPWpGaD
Canagliflozin—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000405	0.00609	CbGpPWpGaD
Canagliflozin—Angiopathy—Hydroxyurea—head and neck cancer	0.000404	0.0177	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—SOD2—head and neck cancer	0.000391	0.00588	CbGpPWpGaD
Canagliflozin—Erythema—Hydroxyurea—head and neck cancer	0.000388	0.017	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—CYP1A1—head and neck cancer	0.000381	0.00573	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—head and neck cancer	0.000373	0.00561	CbGpPWpGaD
Canagliflozin—Convulsion—Vinblastine—head and neck cancer	0.000368	0.0162	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000365	0.0161	CcSEcCtD
Canagliflozin—Urinary tract infection—Fluorouracil—head and neck cancer	0.000347	0.0152	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—NAT2—head and neck cancer	0.000341	0.00512	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NAT2—head and neck cancer	0.000341	0.00512	CbGpPWpGaD
Canagliflozin—Convulsion—Hydroxyurea—head and neck cancer	0.000336	0.0147	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000328	0.0144	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000323	0.00485	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—GSTM1—head and neck cancer	0.00032	0.00482	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—SOD2—head and neck cancer	0.000318	0.00478	CbGpPWpGaD
Canagliflozin—Infection—Hydroxyurea—head and neck cancer	0.000314	0.0138	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—GSTM1—head and neck cancer	0.000313	0.0047	CbGpPWpGaD
Canagliflozin—Dehydration—Docetaxel—head and neck cancer	0.000311	0.0137	CcSEcCtD
Canagliflozin—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00031	0.0136	CcSEcCtD
Canagliflozin—Skin disorder—Hydroxyurea—head and neck cancer	0.000307	0.0135	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000305	0.0134	CcSEcCtD
Canagliflozin—ALB—Folate Metabolism—GPX1—head and neck cancer	0.000303	0.00456	CbGpPWpGaD
Canagliflozin—Breast disorder—Docetaxel—head and neck cancer	0.000302	0.0133	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—DPYD—head and neck cancer	0.000299	0.00449	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—DPYD—head and neck cancer	0.000299	0.00449	CbGpPWpGaD
Canagliflozin—Constipation—Vinblastine—head and neck cancer	0.000297	0.013	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000284	0.0125	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—YAP1—head and neck cancer	0.000283	0.00426	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—YAP1—head and neck cancer	0.000283	0.00426	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—GSTM1—head and neck cancer	0.000281	0.00423	CbGpPWpGaD
Canagliflozin—Erythema—Fluorouracil—head and neck cancer	0.000279	0.0123	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000277	0.00417	CbGpPWpGaD
Canagliflozin—Abdominal pain—Vinblastine—head and neck cancer	0.000274	0.012	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000273	0.012	CcSEcCtD
Canagliflozin—Fatigue—Hydroxyurea—head and neck cancer	0.000273	0.012	CcSEcCtD
Canagliflozin—Constipation—Hydroxyurea—head and neck cancer	0.000271	0.0119	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—CYP1A1—head and neck cancer	0.000266	0.00401	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NAT2—head and neck cancer	0.000263	0.00396	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000263	0.00395	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—head and neck cancer	0.000257	0.00386	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000256	0.00386	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Vinblastine—head and neck cancer	0.000256	0.0112	CcSEcCtD
Canagliflozin—ALB—Selenium Micronutrient Network—SOD2—head and neck cancer	0.000252	0.0038	CbGpPWpGaD
Canagliflozin—Asthenia—Vinblastine—head and neck cancer	0.000249	0.0109	CcSEcCtD
Canagliflozin—Convulsion—Fluorouracil—head and neck cancer	0.000242	0.0106	CcSEcCtD
Canagliflozin—ALB—Selenium Micronutrient Network—GPX1—head and neck cancer	0.000241	0.00362	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—UROD—head and neck cancer	0.000234	0.00353	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000233	0.0102	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—DPYD—head and neck cancer	0.000231	0.00347	CbGpPWpGaD
Canagliflozin—Dizziness—Vinblastine—head and neck cancer	0.000229	0.0101	CcSEcCtD
Canagliflozin—Urinary tract disorder—Docetaxel—head and neck cancer	0.000228	0.01	CcSEcCtD
Canagliflozin—Asthenia—Hydroxyurea—head and neck cancer	0.000227	0.00997	CcSEcCtD
Canagliflozin—Urethral disorder—Docetaxel—head and neck cancer	0.000227	0.00996	CcSEcCtD
Canagliflozin—Infection—Fluorouracil—head and neck cancer	0.000226	0.00993	CcSEcCtD
Canagliflozin—Nervous system disorder—Fluorouracil—head and neck cancer	0.000223	0.00981	CcSEcCtD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.00022	0.0033	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—YAP1—head and neck cancer	0.000219	0.00329	CbGpPWpGaD
Canagliflozin—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000216	0.00325	CbGpPWpGaD
Canagliflozin—Hypotension—Fluorouracil—head and neck cancer	0.000213	0.00934	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—head and neck cancer	0.00021	0.00922	CcSEcCtD
Canagliflozin—Dizziness—Hydroxyurea—head and neck cancer	0.000209	0.00919	CcSEcCtD
Canagliflozin—Nausea—Vinblastine—head and neck cancer	0.000206	0.00905	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—head and neck cancer	0.000201	0.00884	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—head and neck cancer	0.000201	0.00884	CcSEcCtD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.0002	0.003	CbGpPWpGaD
Canagliflozin—Rash—Hydroxyurea—head and neck cancer	0.000199	0.00876	CcSEcCtD
Canagliflozin—Dermatitis—Hydroxyurea—head and neck cancer	0.000199	0.00875	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000197	0.00863	CcSEcCtD
Canagliflozin—Nausea—Hydroxyurea—head and neck cancer	0.000188	0.00825	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000182	0.00274	CbGpPWpGaD
Canagliflozin—Urticaria—Fluorouracil—head and neck cancer	0.000181	0.00794	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—head and neck cancer	0.000181	0.00793	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—head and neck cancer	0.000177	0.00777	CcSEcCtD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000175	0.00263	CbGpPWpGaD
Canagliflozin—Convulsion—Docetaxel—head and neck cancer	0.000174	0.00766	CcSEcCtD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000173	0.0026	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00017	0.00748	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—TYMS—head and neck cancer	0.00017	0.00256	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TYMS—head and neck cancer	0.00017	0.00256	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTM1—head and neck cancer	0.000168	0.00253	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTM1—head and neck cancer	0.000168	0.00253	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Fluorouracil—head and neck cancer	0.000168	0.00737	CcSEcCtD
Canagliflozin—Dry mouth—Docetaxel—head and neck cancer	0.000168	0.00736	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000166	0.0025	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL2—head and neck cancer	0.000165	0.00249	CbGpPWpGaD
Canagliflozin—Infection—Docetaxel—head and neck cancer	0.000163	0.00717	CcSEcCtD
Canagliflozin—Shock—Docetaxel—head and neck cancer	0.000162	0.0071	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—head and neck cancer	0.000161	0.00708	CcSEcCtD
Canagliflozin—Pruritus—Fluorouracil—head and neck cancer	0.000161	0.00707	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—GPX1—head and neck cancer	0.000161	0.00242	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GPX1—head and neck cancer	0.000161	0.00242	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000161	0.00242	CbGpPWpGaD
Canagliflozin—Skin disorder—Docetaxel—head and neck cancer	0.00016	0.00701	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—CYP1A1—head and neck cancer	0.000159	0.0024	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP1A1—head and neck cancer	0.000159	0.0024	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000159	0.00239	CbGpPWpGaD
Canagliflozin—Hypotension—Docetaxel—head and neck cancer	0.000154	0.00674	CcSEcCtD
Canagliflozin—SLC5A2—Disease—NOTCH1—head and neck cancer	0.000152	0.00229	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOTCH1—head and neck cancer	0.000152	0.00229	CbGpPWpGaD
Canagliflozin—Dizziness—Fluorouracil—head and neck cancer	0.000151	0.00661	CcSEcCtD
Canagliflozin—Rash—Fluorouracil—head and neck cancer	0.000144	0.00631	CcSEcCtD
Canagliflozin—Dermatitis—Fluorouracil—head and neck cancer	0.000143	0.0063	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000142	0.00623	CcSEcCtD
Canagliflozin—ALB—Selenium Micronutrient Network—PTGS2—head and neck cancer	0.000142	0.00213	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000142	0.00213	CbGpPWpGaD
Canagliflozin—Fatigue—Docetaxel—head and neck cancer	0.000142	0.00622	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—head and neck cancer	0.000141	0.00617	CcSEcCtD
Canagliflozin—ALB—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000138	0.00207	CbGpPWpGaD
Canagliflozin—Nausea—Fluorouracil—head and neck cancer	0.000135	0.00594	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000134	0.0059	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—TYMS—head and neck cancer	0.000131	0.00198	CbGpPWpGaD
Canagliflozin—Abdominal pain—Docetaxel—head and neck cancer	0.00013	0.00571	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—GSTM1—head and neck cancer	0.00013	0.00195	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—head and neck cancer	0.000126	0.00189	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GPX1—head and neck cancer	0.000124	0.00187	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—head and neck cancer	0.000124	0.00187	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000123	0.00185	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP1A1—head and neck cancer	0.000123	0.00185	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—UROD—head and neck cancer	0.000123	0.00185	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Docetaxel—head and neck cancer	0.000121	0.00532	CcSEcCtD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000121	0.00181	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—head and neck cancer	0.000121	0.00181	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.00012	0.0018	CbGpPWpGaD
Canagliflozin—Asthenia—Docetaxel—head and neck cancer	0.000118	0.00518	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—head and neck cancer	0.000116	0.00511	CcSEcCtD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—head and neck cancer	0.000115	0.00173	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—head and neck cancer	0.000113	0.0017	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—head and neck cancer	0.000113	0.0017	CbGpPWpGaD
Canagliflozin—Dizziness—Docetaxel—head and neck cancer	0.000109	0.00477	CcSEcCtD
Canagliflozin—ABCB1—Metabolism—UROD—head and neck cancer	0.000108	0.00162	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	0.000107	0.0016	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—head and neck cancer	0.000106	0.0016	CbGpPWpGaD
Canagliflozin—Rash—Docetaxel—head and neck cancer	0.000104	0.00455	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—head and neck cancer	0.000104	0.00455	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000103	0.00155	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000102	0.00154	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTEN—head and neck cancer	9.87e-05	0.00149	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTEN—head and neck cancer	9.87e-05	0.00149	CbGpPWpGaD
Canagliflozin—Nausea—Docetaxel—head and neck cancer	9.76e-05	0.00429	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—NAT2—head and neck cancer	9.73e-05	0.00146	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	9.52e-05	0.00143	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—head and neck cancer	9.48e-05	0.00143	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—head and neck cancer	9.48e-05	0.00143	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—head and neck cancer	8.83e-05	0.00133	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—head and neck cancer	8.83e-05	0.00133	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—DPYD—head and neck cancer	8.53e-05	0.00128	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK3—head and neck cancer	8.44e-05	0.00127	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK3—head and neck cancer	8.44e-05	0.00127	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—head and neck cancer	8.27e-05	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—head and neck cancer	8.27e-05	0.00124	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	8.2e-05	0.00123	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—YAP1—head and neck cancer	8.1e-05	0.00122	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK1—head and neck cancer	8.03e-05	0.00121	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK1—head and neck cancer	8.03e-05	0.00121	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—head and neck cancer	8.03e-05	0.00121	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—head and neck cancer	8.03e-05	0.00121	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	7.94e-05	0.00119	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	7.86e-05	0.00118	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	7.83e-05	0.00118	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	7.53e-05	0.00113	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	7.43e-05	0.00112	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—head and neck cancer	7.32e-05	0.0011	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	7.04e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—head and neck cancer	6.97e-05	0.00105	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—head and neck cancer	6.97e-05	0.00105	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.68e-05	0.00101	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UROD—head and neck cancer	6.62e-05	0.000996	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—head and neck cancer	6.44e-05	0.00097	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—head and neck cancer	6.44e-05	0.00097	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—head and neck cancer	6.38e-05	0.00096	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	6.29e-05	0.000946	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.08e-05	0.000915	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	6.04e-05	0.000908	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—head and neck cancer	5.83e-05	0.000878	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—head and neck cancer	5.83e-05	0.000878	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.83e-05	0.000877	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—head and neck cancer	5.69e-05	0.000856	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—head and neck cancer	5.69e-05	0.000856	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.41e-05	0.000814	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.36e-05	0.000806	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	5.35e-05	0.000804	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.31e-05	0.000798	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.26e-05	0.000792	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAT2—head and neck cancer	5.09e-05	0.000766	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	5.06e-05	0.000761	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	4.98e-05	0.000749	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMS—head and neck cancer	4.86e-05	0.000731	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	4.81e-05	0.000724	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—head and neck cancer	4.81e-05	0.000723	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—head and neck cancer	4.77e-05	0.000717	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—head and neck cancer	4.77e-05	0.000717	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.74e-05	0.000713	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.74e-05	0.000713	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—head and neck cancer	4.6e-05	0.000692	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A1—head and neck cancer	4.56e-05	0.000685	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—head and neck cancer	4.5e-05	0.000678	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—DPYD—head and neck cancer	4.47e-05	0.000672	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAT2—head and neck cancer	4.46e-05	0.000672	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—YAP1—head and neck cancer	4.24e-05	0.000638	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	4.18e-05	0.000628	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.11e-05	0.000619	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.98e-05	0.000598	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—DPYD—head and neck cancer	3.91e-05	0.000589	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.74e-05	0.000563	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—YAP1—head and neck cancer	3.71e-05	0.000559	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—head and neck cancer	3.68e-05	0.000554	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	3.41e-05	0.000513	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.36e-05	0.000505	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—head and neck cancer	3.24e-05	0.000488	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.19e-05	0.000479	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.78e-05	0.000418	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—head and neck cancer	2.76e-05	0.000415	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAT2—head and neck cancer	2.75e-05	0.000414	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—head and neck cancer	2.71e-05	0.000408	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—head and neck cancer	2.61e-05	0.000392	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—head and neck cancer	2.55e-05	0.000383	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—head and neck cancer	2.52e-05	0.000379	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK1—head and neck cancer	2.48e-05	0.000373	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DPYD—head and neck cancer	2.41e-05	0.000363	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—head and neck cancer	2.41e-05	0.000363	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A1—head and neck cancer	2.39e-05	0.000359	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—head and neck cancer	2.36e-05	0.000355	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—YAP1—head and neck cancer	2.29e-05	0.000344	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—head and neck cancer	2.23e-05	0.000336	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—head and neck cancer	2.2e-05	0.000332	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—head and neck cancer	2.15e-05	0.000324	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—head and neck cancer	2.11e-05	0.000318	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.09e-05	0.000314	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—head and neck cancer	2.08e-05	0.000313	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—head and neck cancer	1.99e-05	0.0003	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.96e-05	0.000295	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—head and neck cancer	1.76e-05	0.000265	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—head and neck cancer	1.67e-05	0.000251	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—head and neck cancer	1.42e-05	0.000213	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—head and neck cancer	1.37e-05	0.000207	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—head and neck cancer	1.36e-05	0.000205	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.36e-05	0.000204	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—head and neck cancer	1.3e-05	0.000196	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.29e-05	0.000194	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—head and neck cancer	1.24e-05	0.000187	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—head and neck cancer	1.24e-05	0.000186	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—head and neck cancer	1.08e-05	0.000163	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—head and neck cancer	8.73e-06	0.000131	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—head and neck cancer	7.66e-06	0.000115	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.65e-06	0.000115	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—head and neck cancer	7.13e-06	0.000107	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—head and neck cancer	6.68e-06	0.0001	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—head and neck cancer	6.25e-06	9.4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.71e-06	7.09e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—head and neck cancer	3.85e-06	5.79e-05	CbGpPWpGaD
